Cathie Wood’s ARK Invest Shifts Focus to Health-Tech and Genomics with $5.5M Exact Sciences Buy
Cathie Wood's ARK Invest made strategic portfolio adjustments on October 20, 2025, signaling a renewed emphasis on diagnostic innovation. The ARK Genomic Revolution ETF (ARKG) led the charge with a $5.56 million purchase of Exact Sciences (EXAS), reinforcing its position in non-invasive cancer screening technologies.
ARKG also expanded holdings in gene-sequencing pioneer Illumina ($2.77M) and made selective tech bets through Qualcomm ($3.33M) and BYD Co. ($941K). The Autonomous Technology ETF (ARKQ) doubled down on robotic surgery with a $4.09 million Intuitive Surgical position while adding $3.33 million in aerospace defense firm L3Harris.